Paper Details

  1. Home
  2. Paper Details

Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study.

Author: ChetboulValérie, ConcordetDidier, GouniVassiliki, LefebvreHervé P, NicolleAudrey P, PouchelonJean-Louis, SampedranoCarolina Carlos, SaponaroVittorio, SerresFrançois

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pimobendan, an inodilator commonly used for canine degenerative mitral valve disease (MVD), worsened valve regurgitation in dogs with asymptomatic MVD. This suggests that pimobendan may have negative effects on cardiac function and morphology in early stages of MVD.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pimobendan (PIMO) is an inodilator that may have some beneficial effects in canine degenerative mitral valve disease (MVD). However, little information is available about its cardiac effects in dogs without systolic myocardial dysfunction. HYPOTHESIS: Compared to benazepril (BNZ), an an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1892/0891-6640(2007)21[742:caceop]2.0.co;2

データ提供：米国国立医学図書館（NLM）

Pimobendan and Benazepril: A Comparison of Cardiac Effects

This study investigates the potential [cardiac effects] of two different medications, [pimobendan] and [benazepril], in dogs with [mild degenerative mitral valve disease]. The researchers conducted a [prospective, controlled, blinded, and randomized study] to compare the effects of these medications on heart function and valve morphology.

Imagine a desert with two types of camels, both experiencing a heart condition (degenerative mitral valve disease). One camel (pimobendan group) is given a new type of medicine, while the other (benazepril group) receives a standard treatment. This study compares the effects of these different medicines on the camels' hearts.

Pimobendan: Potential Adverse Cardiac Effects

The study found that [pimobendan] may have [adverse cardiac functional and morphologic effects] in dogs with [mild degenerative mitral valve disease]. While it improved some aspects of heart function, it also led to increased [valve regurgitation] and more severe [mitral valve lesions].

Navigating the Desert of Cardiac Health

This research highlights the importance of careful consideration when prescribing medications, especially for [heart conditions]. It underscores the need for further investigation to fully understand the potential benefits and risks associated with different treatments.

Dr.Camel's Conclusion

This study reminds us that even in the vast desert of medical knowledge, there are still many unknowns. The comparison of [pimobendan] and [benazepril] reveals the need for cautious and informed treatment decisions, ensuring the best possible outcomes for our patients. It's a reminder that just as a wise camel guide navigates the desert with care and foresight, healthcare professionals must approach treatments with a similar level of attentiveness and caution.

Date :
  1. Date Completed 2007-09-20
  2. Date Revised 2019-05-13
Further Info :

Pubmed ID

17708394

DOI: Digital Object Identifier

10.1892/0891-6640(2007)21[742:caceop]2.0.co;2

Related Literature

Article Analysis
・Effects of benazepril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.